Lovastatin-mediated changes in human tendon cells

Statins are among the most widely prescribed drugs worldwide. Numerous studies have shown their beneficial effects in prevention of cardiovascular disease through cholesterol-lowering and anti-atherosclerotic properties. Although some statin patients may experience muscle-related symptoms, severe si...

Full description

Bibliographic Details
Main Authors: Kuzma-Kuzniarska, M, Cornell, H, Moneke, M, Carr, A, Hulley, P
Format: Journal article
Language:English
Published: Wiley 2015
_version_ 1797074756130832384
author Kuzma-Kuzniarska, M
Cornell, H
Moneke, M
Carr, A
Hulley, P
author_facet Kuzma-Kuzniarska, M
Cornell, H
Moneke, M
Carr, A
Hulley, P
author_sort Kuzma-Kuzniarska, M
collection OXFORD
description Statins are among the most widely prescribed drugs worldwide. Numerous studies have shown their beneficial effects in prevention of cardiovascular disease through cholesterol-lowering and anti-atherosclerotic properties. Although some statin patients may experience muscle-related symptoms, severe side effects of statin therapy are rare, primarily due to extensive first-pass metabolism in the liver. Skeletal muscles appear to be the main site of side effects; however, recently some statin-related adverse effects have been described in tendon. The mechanism behind these side effects remains unknown. This is the first study that explores tendon-specific effects of statins in human primary tenocytes. The cells were cultured with different concentrations of lovastatin for up to 1 week. No changes in cell viability or morphology were observed in tenocytes incubated with therapeutic doses. Short-term exposure to lovastatin concentrations outside the therapeutic range had no effect on tenocyte viability; however, cell migration was reduced. Simvastatin and atorvastatin, two other drug family members, also reduced the migratory properties of the cells. Prolonged exposure to high concentrations of lovastatin induced changes in cytoskeleton leading to cell rounding and decreased levels of mRNA for matrix proteins, but increased BMP-2 expression. Gap junctional communication was impaired but due to cell shape change and separation rather than direct gap junction inhibition. These effects were accompanied by inhibition of prenylation of Rap1a small GTPase. Collectively, we showed that statins in a dose-dependent manner decrease migration of human tendon cells, alter their expression profile and impair the functional network, but do not inhibit gap junction function.
first_indexed 2024-03-06T23:40:47Z
format Journal article
id oxford-uuid:6f3ddcda-c602-45be-902b-73b5c94d430b
institution University of Oxford
language English
last_indexed 2024-03-06T23:40:47Z
publishDate 2015
publisher Wiley
record_format dspace
spelling oxford-uuid:6f3ddcda-c602-45be-902b-73b5c94d430b2022-03-26T19:29:27ZLovastatin-mediated changes in human tendon cellsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6f3ddcda-c602-45be-902b-73b5c94d430bEnglishSymplectic Elements at OxfordWiley2015Kuzma-Kuzniarska, MCornell, HMoneke, MCarr, AHulley, PStatins are among the most widely prescribed drugs worldwide. Numerous studies have shown their beneficial effects in prevention of cardiovascular disease through cholesterol-lowering and anti-atherosclerotic properties. Although some statin patients may experience muscle-related symptoms, severe side effects of statin therapy are rare, primarily due to extensive first-pass metabolism in the liver. Skeletal muscles appear to be the main site of side effects; however, recently some statin-related adverse effects have been described in tendon. The mechanism behind these side effects remains unknown. This is the first study that explores tendon-specific effects of statins in human primary tenocytes. The cells were cultured with different concentrations of lovastatin for up to 1 week. No changes in cell viability or morphology were observed in tenocytes incubated with therapeutic doses. Short-term exposure to lovastatin concentrations outside the therapeutic range had no effect on tenocyte viability; however, cell migration was reduced. Simvastatin and atorvastatin, two other drug family members, also reduced the migratory properties of the cells. Prolonged exposure to high concentrations of lovastatin induced changes in cytoskeleton leading to cell rounding and decreased levels of mRNA for matrix proteins, but increased BMP-2 expression. Gap junctional communication was impaired but due to cell shape change and separation rather than direct gap junction inhibition. These effects were accompanied by inhibition of prenylation of Rap1a small GTPase. Collectively, we showed that statins in a dose-dependent manner decrease migration of human tendon cells, alter their expression profile and impair the functional network, but do not inhibit gap junction function.
spellingShingle Kuzma-Kuzniarska, M
Cornell, H
Moneke, M
Carr, A
Hulley, P
Lovastatin-mediated changes in human tendon cells
title Lovastatin-mediated changes in human tendon cells
title_full Lovastatin-mediated changes in human tendon cells
title_fullStr Lovastatin-mediated changes in human tendon cells
title_full_unstemmed Lovastatin-mediated changes in human tendon cells
title_short Lovastatin-mediated changes in human tendon cells
title_sort lovastatin mediated changes in human tendon cells
work_keys_str_mv AT kuzmakuzniarskam lovastatinmediatedchangesinhumantendoncells
AT cornellh lovastatinmediatedchangesinhumantendoncells
AT monekem lovastatinmediatedchangesinhumantendoncells
AT carra lovastatinmediatedchangesinhumantendoncells
AT hulleyp lovastatinmediatedchangesinhumantendoncells